Hims & Hers Health, Inc.

As of June 30, 2026, Hims & Hers Health, Inc. Class A carries a market capitalization of 6.39B, placing it among publicly traded companies globally. Its enterprise value stands at 6.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hims & Hers Health, Inc. Class A's next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Hims & Hers Health, Inc. Class A has 233.30M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.01, and the price-to-book ratio stands at 24.43.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.96B versus a market cap of 6.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hims & Hers Health, Inc. Class A maintains a current ratio of 0.93, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A posted a negative return on equity (ROE) of -32.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.16, reflecting losses generated across the asset base. The company generates approximately 929,454.97 in revenue per employee across its workforce of 2,240.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.09 indicates how many times Hims & Hers Health, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A recorded an income tax benefit of -17.43M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -132.17M and -114.74M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Hims & Hers Health, Inc. Class A's stock has declined approximately 40.95% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A generated 2.08B in revenue and converted that into -114.74M in net income, yielding earnings per share of -0.48. EBITDA reached -54.39M, while operating income came in at -124.83M.

As of June 30, 2026, Hims & Hers Health, Inc. Class A holds 679.42M in cash and equivalents against 1.25B in total debt, resulting in a net debt position of 610.31M. Total book value stands at 261.80M, with working capital of -79.67M providing operational flexibility.

Hims & Hers Health, Inc. Class A produced 212.82M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -163.03M in capital expenditures, free cash flow totaled 49.79M - equivalent to 0.22 per share.

Over the twelve months ended June 30, 2026, Hims & Hers Health, Inc. Class A posted a gross margin of 68.43, reflecting its pricing power and cost economics. The operating margin of -5.99 and net profit margin of -5.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.76, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.61, meaning Hims & Hers Health, Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Hims & Hers Health, Inc. Class A has an Altman Z-Score of 2.17, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.